ALT Stock Overview
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Altimmune, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.20 |
52 Week High | US$14.84 |
52 Week Low | US$2.09 |
Beta | 0.059 |
1 Month Change | -16.76% |
3 Month Change | -22.83% |
1 Year Change | 45.16% |
3 Year Change | -49.37% |
5 Year Change | 149.13% |
Change since IPO | -96.97% |
Recent News & Updates
Buy Altimmune's Potential Market Disruption With Pemvidutide
Apr 12Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Mar 27Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Feb 27Recent updates
Buy Altimmune's Potential Market Disruption With Pemvidutide
Apr 12Altimmune: Despite HepTcell Failure, Differentiation Of Obesity Drug In Place
Mar 27Altimmune: Taking On Toughest Of Rivals In Obesity - I'm Unconvinced By Recent Rally
Feb 27Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment
Feb 12Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Feb 10Thoroughly Derisked, Altimmune Is Now A Great Buy
Jan 10Is Altimmune (NASDAQ:ALT) In A Good Position To Deliver On Growth Plans?
Oct 11We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
Jun 27Companies Like Altimmune (NASDAQ:ALT) Are In A Position To Invest In Growth
Feb 12We Think Altimmune (NASDAQ:ALT) Can Afford To Drive Business Growth
Oct 27Altimmune: Overreaction On NASH Data Creates Buying Opportunity
Sep 15Reassessing Altimmune
Sep 07Altimmune sets new 52-week high on rising volume
Aug 31Altimmune Q2 2022 Earnings Preview
Aug 10Altimmune: Several Catalysts In 2 Large Market Indications This Year
Jun 29Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Jun 27Altimmune's New Avatar As A Liver Disease Player
Apr 07Here's Why We're Watching Altimmune's (NASDAQ:ALT) Cash Burn Situation
Feb 01Altimmune: Changing Focus To Pemvidutide In 2022
Jan 03Altimmune: Changing The Thesis
Oct 16Here's Why Altimmune, Inc.'s (NASDAQ:ALT) CEO Compensation Is The Least Of Shareholders Concerns
Sep 17We're Hopeful That Altimmune (NASDAQ:ALT) Will Use Its Cash Wisely
Aug 06Altimmune: NASH And Obesity At The End Of The COVID Tunnel
Jul 27Altimmune rises 5% on positive ALT-801 data in early-stage trial of overweight volunteers
Jun 16Altimmune gains 7% after AdCOVID shows strong immune response against COVID-19 variant in preclinical study
May 26Altimmune reports encouraging AdCOVID data in SARS-CoV-2 challenged mice
May 10We Think Altimmune (NASDAQ:ALT) Can Easily Afford To Drive Business Growth
May 02Investors Who Bought Altimmune (NASDAQ:ALT) Shares A Year Ago Are Now Up 459%
Mar 21Shareholder Returns
ALT | US Biotechs | US Market | |
---|---|---|---|
7D | 4.5% | 0.4% | 1.0% |
1Y | 45.2% | 0.9% | 21.9% |
Return vs Industry: ALT exceeded the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: ALT exceeded the US Market which returned 24.9% over the past year.
Price Volatility
ALT volatility | |
---|---|
ALT Average Weekly Movement | 16.2% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALT's share price has been volatile over the past 3 months.
Volatility Over Time: ALT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 59 | Vipin Garg | altimmune.com |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
Altimmune, Inc. Fundamentals Summary
ALT fundamental statistics | |
---|---|
Market cap | US$510.45m |
Earnings (TTM) | -US$88.45m |
Revenue (TTM) | US$426.00k |
1,198x
P/S Ratio-5.8x
P/E RatioIs ALT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALT income statement (TTM) | |
---|---|
Revenue | US$426.00k |
Cost of Revenue | US$65.80m |
Gross Profit | -US$65.37m |
Other Expenses | US$23.07m |
Earnings | -US$88.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.25 |
Gross Margin | -15,345.77% |
Net Profit Margin | -20,762.21% |
Debt/Equity Ratio | 0% |
How did ALT perform over the long term?
See historical performance and comparison